Navigation Links
Silence Therapeutics' Lead RNA Interference Therapeutic Prevents Spread of Cancer to Lungs
Date:11/10/2010

tatic processes that involve blood flow to the lung," stated Klaus Giese, Ph.D., chief scientific officer at Silence Therapeutics.  "Importantly, these data provide us with evidence that Atu027, which targets vascular endothelial cells, may be modulating not only the tumor vasculature itself, but the pulmonary vasculature as well."

"We are very pleased to be able to continue to identify the mechanisms that drive Atu027's therapeutic activity while concurrently advancing the product through its ongoing Phase 1 study.  Building this collection of novel data on Atu027 will only serve to inform our ongoing development efforts and allow us to maximize the opportunity for success with this program," said Philip Haworth, Ph.D., chief executive officer of Silence Therapeutics.

Atu027, a liposomal AtuRNAi™ formulation in clinical development for systemic cancer indications, is one of the most clinically advanced RNAi therapeutics in the area of oncology.  In June 2009, Silence initiated an open-label, single-centre, dose-escalation Phase I study with Atu027 in patients with advanced solid (malignant) tumors involving single, as well as, repeated intravenous administration.  The study is expected to be completed early in the second half of 2011.

Notes for editors

About Silence Therapeutics plc (www.silence-therapeutics.com)

Silence Therapeutics plc (AIM: SLN) is a leading global biotechnology company dedicated to the discovery, development and delivery of targeted, systemic RNA interference (RNAi) therapeutics for the treatment of serious diseases.  The company possesses multiple proprietary short interfering RNA (siRNA) delivery technology platforms including AtuPLEX™, a system that enables the functional delivery of siRNA molecules to targeted diseased tissues and cells, while increasing their bioavailability and intracellular upta
'/>"/>

SOURCE Silence Therapeutics plc
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. National Ovarian Cancer Coalition and PureOlogy to Host First Annual NOCC and PureOlogys Walk to Break the Silence on Ovarian Cancer
2. Silence Therapeutics to Present at 12th Annual BIO CEO & Investor Conference
3. Silence Therapeutics Appoints New Vice President of Research
4. Silence Therapeutics Issued Novel RNAi Patent Covering High-Value Cancer Target in United States
5. Silence Therapeutics Expands RNAi Structural Modification IP Portfolio With Issuance of New U.S. Patent
6. Silence Therapeutics Partner Quark Signs Exclusive Option Agreement With Novartis for Development and Commercialisation of QPI-1002
7. Silence Therapeutics Receives Comprehensive Protection for RNAi Structural Modification Technology in Single European Patent
8. Halozyme Therapeutics Reports 2008 Second Quarter Financial Results
9. Repair Stem Cell Institute Announces Industrys First Standards of Excellence for Global Stem Cell Treatment Centers to Protect Patients from Less-than-Competent Therapeutics
10. Amsterdam Molecular Therapeutics Reports Half Year Results 2008
11. BN ImmunoTherapeutics Announces Partnership With National Cancer Institute
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/31/2014)... LONDON , July 31, 2014  Smith ... the global medical technology business, today announced its ... of the HAT-TRICK™ Lesser Toe Repair System. Comprised ... includes products for metatarsophalangeal (MTP) ligament repair and ... all-PEEK implant for proximal Inter-phalanges (PIP) fusion, also ...
(Date:7/31/2014)... The global market for molecular diagnostics is expected to ... new study by Grand View Research, Inc. Growing demand ... of advanced cancer diagnostic technologies are expected to be ... years. Moreover, the growing global base of geriatric population ... triggering lifestyle habits such as smoking and excessive alcohol ...
(Date:7/31/2014)... 31, 2014 SoundConnect , ... company, is proud to announce the addition of ... Adobe Connect’s elearning tools to quickly deploy and ... with training tools for desktop and mobile learning ... is the perfect online training solution, enabling organizations ...
(Date:7/30/2014)... , July 30, 2014 Regulus ... biopharmaceutical company leading the discovery and development of innovative ... financial results and highlights for the quarter ended June ... U.S. financial markets close. Regulus will ... 6, 2014, at 5:00 pm Eastern Daylight Time to ...
Breaking Biology Technology:Smith & Nephew scores a HAT-TRICK with its entry into the high-growth hammer toe repair market 2Smith & Nephew scores a HAT-TRICK with its entry into the high-growth hammer toe repair market 3Smith & Nephew scores a HAT-TRICK with its entry into the high-growth hammer toe repair market 4Molecular Diagnostics Market - Global Industry Size, Share, Trends, Analysis, Players, Opportunity, Outlook and Forecast From 2014 to 2020 2Molecular Diagnostics Market - Global Industry Size, Share, Trends, Analysis, Players, Opportunity, Outlook and Forecast From 2014 to 2020 3Molecular Diagnostics Market - Global Industry Size, Share, Trends, Analysis, Players, Opportunity, Outlook and Forecast From 2014 to 2020 4Molecular Diagnostics Market - Global Industry Size, Share, Trends, Analysis, Players, Opportunity, Outlook and Forecast From 2014 to 2020 5SoundConnect Enhances Portfolio with Adobe Connect Learning Management System (LMS) 2Regulus Announces Timing for Second Quarter 2014 Financial Results Webcast and Conference Call 2Regulus Announces Timing for Second Quarter 2014 Financial Results Webcast and Conference Call 3
... announced that it has been awarded a $1.9 million ... the National Institute of Allergy and Infectious Diseases (NIAID) ... grant will be used to perform additional preclinical toxicology ... hormone product, which is being developed as a potential ...
... SAN MARINO, Calif., Dec. 16 Epeius ... systems, has received,two additional European patents for ... enable precision gene delivery to primary cancers ... body. With profound,demonstrations of clinical benefit and ...
... -- Epitomics, Inc., the world,s sole provider of ... the appointment of Zhiqiang An, Ph.D. as Chief Scientific ... Laboratories, where he was Director of Biologics Research. He ... and development in the biotech and pharmaceutical industries, focusing ...
Cached Biology Technology:Bolder BioTechnology Receives $1.9 Million NIH Grant to Continue Development of Long-Acting Growth Hormone Product 2Epeius Biotech Awarded Patents in Europe for Targeted Genetic Anti-Cancer Medicine: Company Expands Impressive Intellectual Property Estate 2Epitomics Appoints Dr. Zhiqiang An as Chief Scientific Officer 2Epitomics Appoints Dr. Zhiqiang An as Chief Scientific Officer 3
(Date:7/31/2014)... According to the U.S. Census Bureau, Latinos are the ... of the population. Approximately one-third of Latinos are ... obese compared to non-Hispanic Whites. , NYU College ... candidate, has sought to identify the factors that contribute ... qualitative studies that focused on food patterns in Latina ...
(Date:7/31/2014)... Researchers who studied 100 twin pairs have identified a gene ... less than six hours of sleep per night. The ... effects of sleep deprivation. , Results show that a participant ... had an average nightly sleep duration of only five hours, ... twin, who slept for about six hours and five minutes ...
(Date:7/31/2014)... hazard lurks beneath many of the roughly 156,000 ... hazard is corrosion in parts of underground gas ... and contamination of groundwater, a source of drinking ... states have reported many rapidly corroding gas storage ... are generally associated with use of gasoline-ethanol blends ...
Breaking Biology News(10 mins):NYU research looks to combat US Latina immigrant obesity 2Study of twins discovers gene mutation linked to short sleep duration 2NIST corrosion lab tests suggest need for underground gas tank retrofits 2
... . The scientists observed that the impact of ... study have been published in the current online issue of the ... to show that children who are exposed to tobacco smoke prenatally ... of developing abnormal behavioral symptoms when they are of school age," ...
... , WALL, N.J., Dec. 9 ... a leader in finger-based biometric identification solutions, today ... most respected security publications, named BIO-key International the ... Control sub-category Biometrics. , (Logo: http://www.newscom.com/cgi-bin/prnh/20050509/BIOKEYLOGO ...
... in old age or diabetes, leads to low blood flow ... tissues. Such blockages can require amputation resulting in loss of ... Hopkins have developed therapies that increase blood flow, improve movement ... findings, published online last week in the early edition of ...
Cached Biology News:Study confirms association between tobacco smoke and behavioral problems in children 2BIO-key(R) Selected as 2009 Industry Innovator in Biometrics by SC Magazine 2BIO-key(R) Selected as 2009 Industry Innovator in Biometrics by SC Magazine 3Gene therapy and stem cells save limb 2Gene therapy and stem cells save limb 3
... Rotor designed for use in the ... Centra-MP4/MP4R*. A translucent lid is included ... rotor design provides excellent chemical resistance ... Polypropylene rotors are fully compatible with ...
Medium bottle for hybridization 250 x 35mm...
Extra Large bottle for hybridization 300 x 70mm...
CQCS kit for first KR 4i , (first unit)....
Biology Products: